INTRODUCTION {#S1}
============

Inflammation is required for activation of innate and adaptive immunity, which is essential for host defense against invading pathogens such as viruses and bacteria^[@R1],[@R2]^. The inflammatory response must be resolved after the pathogens are cleared because unchecked inflammation can cause tissue damage and organ failure in the host. However, the mechanism that controls resolution of the inflammatory response is incompletely understood.

Lipopolysaccharide (LPS; also known as endotoxin) is a structural component of the outer membranes of Gram-negative bacteria and is a potent inducer of inflammation^[@R3]^. LPS binds to and signals through Toll-like receptor 4 (TLR4), leading to rapid release of pro-inflammatory cytokines, such as tumor necrosis factor (TNF), and chemokines. Subsequently, TNF acts through its membrane receptor 1 complex I (TNF-R1 Complex I)^[@R4]--[@R6]^ to activate multiple downstream effectors, such as MAP kinases JNK, p38 and ERK, and the transcription factor NF-κB, to further induce the production of pro-inflammatory cytokines and chemokines, including interleukin 6 (IL-6), IL-1β and MCP-1, thereby amplifying the inflammatory response^[@R7],[@R8]^.

A complex transcriptional regulatory network is involved in the control of LPS-induced inflammatory response^[@R9],[@R10]^. The expression of a large number of LPS-induced genes is controlled by a transcriptional regulatory circuit that is composed of three transcription factors: NF-κB is the initiator, C/EBP-δ the amplifier, and ATF-3 the attenuator^[@R9]^. In this circuit, the immediate activation of NF-κB triggers the early induction of LPS-responsive genes. Concomitantly, NF-κB binds to the promoter of *Cebpd* and activates its transcription. C/EBP-δ in turn binds to the promoters of LPS-induced target genes, including pro-inflammatory cytokines, and acts together with NF-κB to stimulate maximal transcription of numerous LPS-target genes^[@R9]^, thereby contributing to the amplification and persistence of the inflammation. C/EBP-δ also autoinduces its transcription^[@R11]^. In parallel, NF-κB induces the transcription of *Atf3*. ATF-3 subsequently binds to the *Cebpd* promoter and suppresses its transcription, thereby attenuating the inflammatory response^[@R9]^. However, in the absence of ATF-3, the transcription of *Cebpd* still declines quickly, as it does in wild-type controls^[@R11]^. Thus, other mechanism(s) must exist to repress *Cebpd* transcription to switch off the amplification, thereby resolving the inflammatory response.

The transcription factor Miz1 was first identified as a Myc-interacting protein^[@R12],[@R13]^, having an N-terminal poxvirus and zinc-finger (POZ) domain, which is required its transcriptional activity, and thirteen zinc fingers at its C-terminus^[@R12]^. Miz1 plays a critical role in regulation of proliferation, differentiation, cell cycle progression and apoptosis through the transcriptional activation and repression of its target genes^[@R11],[@R12],[@R14],[@R15]^. Miz1 in the cytoplasm^[@R12],[@R16]--[@R19]^ suppresses LPS- and TNF-induced inflammatory responses by specifically interfering with JNK activation, independently of its transcriptional activity^[@R16]--[@R18],[@R20]^. It is not known whether nuclear Miz1 plays a role in regulation of inflammation and if so, what the mechanism is. Here, we report that nuclear Miz1 is required for termination of LPS-induced inflammation by repressing *Cebpd* transcription, thereby constraining acute lung injury and reducing mortality in mice. Thus, Miz1 provides a critical transcriptional checkpoint that prevents the host from excessive inflammatory response and tissue damage.

RESULTS {#S2}
=======

Miz1 suppresses lung inflammation and injury {#S3}
--------------------------------------------

To study the role of nuclear Miz1 in lung inflammation, the Miz1 POZ domain was genetically disrupted in the lungs by intratracheal administration of an adenovirus encoding Cre recombinase (Ad-Cre) into *Miz1*(POZ)^fl/fl^ mice, in which the coding exons of the POZ domain of Miz1 were flanked by *lox*P sites^[@R21]--[@R23]^. Thirty d later, allele-specific genomic PCR and RT-PCR revealed deletion of the Miz1 POZ domain in the lungs of Ad-Cre-treated *Miz1*(POZ)^fl/fl^ mice (*Miz1*^ΔPOZ/lung^) but not the control mice ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). Immunoblotting analysis of whole lung homogenates of *Miz1*^ΔPOZ/lung^ mice revealed a decrease in Miz1 molecular mass that was consistent with the deletion of the POZ domain ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). The truncated Miz1 protein was detected by immunoblotting in primary alveolar epithelial type II (ATII) isolated from Miz1^ΔPOZ/lung^ mice ([Fig. 1b](#F1){ref-type="fig"}). By contrast, the Miz1 POZ domain was not deleted in hematopoietic-derived cells under this condition, as analyzed by semi-quantitative or real-time RT-PCR ([Supplementary Fig. 1c,d](#SD1){ref-type="supplementary-material"}). This result is consistent with previous reports that intratracheal Ad-Cre infection results in efficient recombination in the alveolar epithelium^[@R21],[@R23]--[@R25]^.

To determine whether nuclear Miz1 regulates lung inflammation, we used a murine model of intratracheal LPS-induced inflammation and acute lung injury^[@R26]^. Wild-type or *Miz1*(POZ)^fl/fl^ mice were intratracheally infected with Ad-Cre or Ad-null for 30 d, and then treated with or without intratracheal LPS (6 mg/kg) for 2 d. Histopathological examination revealed that the lungs of *Miz1*^ΔPOZ/lung^ mice exhibited severe alveolar damage, characterized by interstitial edema and increased fluid and debris in the air space, compared with the control mice ([Fig. 1c](#F1){ref-type="fig"}). Inflammatory cell numbers and protein concentrations were significantly increased in the bronchoalveolar lavage (BAL) fluid of *Miz1*^ΔPOZ/lung^ mice ([Fig. 1d](#F1){ref-type="fig"}, [Supplementary Fig. 1e,f](#SD1){ref-type="supplementary-material"}). The airway epithelium was intact in both Ad-Cre- and Ad-null-infected *Miz1*(POZ)^fl/fl^ mice (prior to LPS challenge), when the permeability of the alveolar capillary membrane was analyzed by intravenously injecting Evans blue ([Supplementary Fig. 1g,h](#SD1){ref-type="supplementary-material"}) or FITC-labeled dextran molecule (4 kDa) ([Supplementary Fig. 1i](#SD1){ref-type="supplementary-material"}), or by lung water content ([Supplementary Fig. 1j](#SD1){ref-type="supplementary-material"}). This suggests that the hyper-inflammatory state of LPS-treated *Miz1*^ΔPOZ/lung^ mice was not due to a leak of the airway epithelium induced by loss of the Miz1 POZ domain.

The resolution of lung inflammation and injury was markedly delayed in *Miz1*^ΔPOZ/lung^ mice ([Fig. 1e](#F1){ref-type="fig"}). Neither Ad-null nor Ad-Cre-treated *Miz1*(POZ)^fl/fl^ mice died after treatment with a low dose of LPS (6 mg/kg) ([Supplementary Fig. 1k](#SD1){ref-type="supplementary-material"}). However, 50% of Ad-Cre-treated *Miz1*(POZ)^fl/fl^ mice died within 4 d of treatment with a high dose of LPS (12 mg/kg), whereas all of Ad-null-treated mice survived under the same conditions ([Fig. 1f](#F1){ref-type="fig"}). Thus, deletion of the Miz1 POZ domain in the lung renders mice highly susceptible to LPS-induced inflammation, acute lung injury and mortality *in vivo*.

To demonstrate that disruption of the Miz1 POZ domain in lung epithelial cells is sufficient to augment LPS-induced inflammation and lung injury, *Miz1*(POZ)^fl/fl^ mice were intratracheally infected with an adenovirus that targets Cre recombinase specifically to lung epithelial cells (Ad-SPC-Cre)^[@R27]^. The Miz1 POZ domain was deleted in ATII but not hematopoietic-derived cells of the lungs from intratracheal Ad-SPC-Cre-treated mice ([Supplementary Fig. 1c,d](#SD1){ref-type="supplementary-material"}) and Ad-SPC-Cre-infected mice had augmented LPS-induced lung inflammation and injury similar to Ad-Cre-treated mice ([Fig. 1g](#F1){ref-type="fig"}). Thus, Miz1 in lung epithelial cells plays a critical role in LPS-induced lung inflammation and injury. However, Miz1 in other cell types, such as hematopoietic-derived cells, may also have an important role in LPS-induced inflammation. Using the approach of bone marrow transplantation, we found that lethally irradiated wild-type recipient mice reconstituted with Miz1(ΔPOZ) bone marrow cells ([Supplementary Fig. 1l,m](#SD1){ref-type="supplementary-material"}) had augmented lung inflammation and severe tissue damage induced by intratracheal LPS compared with those reconstituted with wild-type bone marrow cells ([Supplementary Fig. 1n](#SD1){ref-type="supplementary-material"}). Thus, Miz1 in hematopoietic cells is also important in regulation of lung inflammation.

Miz1 inhibits pro-inflammatory cytokine production {#S4}
--------------------------------------------------

LPS induces rapid production and release of pro-inflammatory cytokines and chemokines, which are sufficient to induce lung inflammation and acute injury in mice and humans^[@R28]^. When Ad-Cre- or Ad-null-infected *Miz1*(POZ)^fl/fl^ mice were treated with LPS for 8 h, the production of TNF, IL-6, IL-1β and MCP-1 was significantly elevated in *Miz1*^ΔPOZ/lung^ mice compared with the control mice ([Fig. 2a--d](#F2){ref-type="fig"}). By contrast, the concentrations of the anti-inflammatory cytokine IL-10 were not affected by loss of the Miz1 POZ domain ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). Thus, the hyper-sensitivity of *Miz1*^ΔPOZ/lung^ mice to LPS was associated with an increase in pro-inflammatory cytokines and chemokines.

To determine whether Miz1 regulates the inflammatory response in ATII cells, which are critical players in the initiation and amplification of lung inflammation^[@R29]^, primary ATII cells were isolated from *Miz1*(POZ)^fl/fl^ mice \[ATII-Miz1(POZ)^fl/fl^\], infected with Ad-Cre or Ad-null and treated with or without TNF or LPS. Immunoblotting analysis revealed that cells infected with Ad-Cre, but not Ad-null, expressed the truncated Miz1 protein ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). TNF- or LPS-induced production of IL-6, IL-1β and MCP-1 was significantly increased in Ad-Cre-treated ATII-Miz1(POZ)^fl/fl^ cells compared with Ad-null-treated cells ([Fig. 2e](#F2){ref-type="fig"}). Similar results were obtained in TNF- or LPS-treated stable murine type II-like lung epithelial cells \[MLE-12--Miz1(ΔPOZ) or MLE12--Miz1(WT)\] ([Fig. 2f](#F2){ref-type="fig"}), in which endogenous Miz1 was stably knocked down by specific shRNA \[(MLE-12--Miz1(KD)\] ([Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}) and simultaneously the Miz1(ΔPOZ) mutant or wild-type Miz1, which contains silent mutations to make it resistant to shRNA against endogenous Miz1, was stably expressed in amounts similar to the endogenous protein ([Supplementary Fig. 2d](#SD1){ref-type="supplementary-material"}). The effect of Miz1(ΔPOZ) mutant was not due to its potential dominant-negative effect, since knockdown of the Miz1(ΔPOZ) truncated protein (which results in loss of both nuclear and cytoplasmic functions of Miz1) further augmented TNF-induced IL-6 production ([Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}). Thus, nuclear Miz1 suppresses LPS- or TNF-induced production of pro-inflammatory cytokines and chemokines *in vivo* and *in vitro*. Loss of the Miz1 POZ domain did not affect the inflammatory response induced by TLR3 agonist poly(I:C) ([Supplementary Fig. 2f](#SD1){ref-type="supplementary-material"}), suggesting that Miz1 may specifically regulate TLR4- and TNF-RI-mediated inflammation.

Miz1 suppresses inflammation in *P. aeruginosa* pneumonia {#S5}
---------------------------------------------------------

We sought to determine whether the augmented inflammation by loss of the Miz1 POZ domain protects mice against bacterial infection. When mice were inoculated intranasally with *Pseudomonas aeruginosa,* a Gram-negative bacterium, there was increased production of pro-inflammatory cytokines and chemokines ([Fig. 3a](#F3){ref-type="fig"}), correlated with reduced bacterial load ([Fig. 3b](#F3){ref-type="fig"}), in the lungs of *Miz1*^Δ*POZ/lung*^ mice. Accordingly, *Miz1*^Δ*POZ/lung*^ mice had reduced mortality ([Fig. 3c](#F3){ref-type="fig"}; Mice that did not die within 4 d recovered and survived), consistent with previous reports that a deficiency in the innate immune response protects the host from a sterile challenge (LPS) while sensitizes them to live bacterial infection, or vice versa^[@R30]--[@R36]^.

Nuclear Miz1 does not affect TNF-induced cell death or growth {#S6}
-------------------------------------------------------------

We determined whether the hyper-sensitivity of *Miz1*^ΔPOZ/lung^ mice to LPS could be the result of altered apoptosis or proliferation of the lung epithelial cells. TUNEL assays revealed similar percentages of apoptotic cells in the lungs of the control and *Miz1*^ΔPOZ/lung^ mice ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Apoptotic cell death assays showed no significant difference in apoptosis between TNF- or LPS-treated primary ATII-Miz1(ΔPOZ) cells and the control cells ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}). Similar results were obtained with stable MLE-12--Miz1(ΔPOZ) and MLE12--Miz1(WT) cells ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Furthermore, there was no significant difference in cell proliferation between stable MLE-12--Miz1(ΔPOZ) and MLE12--Miz1(WT) cells under non-stimulated conditions or upon TNF stimulation ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). These data are consistent with previous reports that Miz1 regulates apoptosis and proliferation in a stimulus and cell-type dependent manner^[@R11],[@R14],[@R17],[@R37]^. Thus, the augmented inflammatory response in LPS-treated *Miz1*^ΔPOZ/lung^ mice is not caused by deregulation of epithelial cell apoptosis or proliferation.

Nuclear Miz1 does not regulate MAP kinases or NF-κB {#S7}
---------------------------------------------------

We determined whether loss of the Miz1 POZ domain augments activation of MAP kinases or NF-κB. When lung lysates of LPS-treated or untreated mice were examined, loss of the Miz1 POZ domain did not affect LPS-induced activation of MAP kinases JNK, p38, or ERK, or IKK ([Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}), which is essential for activation of NF-κB^[@R5]^, consistent with our previous report^[@R17]^. Similar results were obtained with TNF- or LPS-treated MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells ([Supplementary Fig. 3f--h](#SD1){ref-type="supplementary-material"}). Thus, the hyper-susceptibility of *Miz1*^ΔPOZ/lung^ mice to LPS is not caused by altering activation of MAP kinases or NF-κB.

Nuclear Miz1 terminates C/EBP-δ expression {#S8}
------------------------------------------

We determined the effect of loss of the Miz1 POZ domain on expression of C/EBP transcription factors, which have been reported to be critical for regulation of the inflammatory response^[@R9],[@R38]^. Protein and mRNA abundance of C/EBP-δ was increased when the control Ad-null-treated mice were challenged by LPS ([Fig. 4a](#F4){ref-type="fig"}, compare lane 2 to lane 1), consistent with previous reports^[@R38]^. Protein and mRNA expression of C/EBP-δ, but not C/EBP-α or C/EBP-β, were significantly increased in *Miz1*^ΔPOZ/lung^ mice, and this increase was further augmented by LPS ([Fig. 4a](#F4){ref-type="fig"}). Loss of the Miz1 POZ domain also up-regulated protein and/or mRNA abundance of C/EBP-δ in primary lung ATII cells ([Fig. 4b,c](#F4){ref-type="fig"}) or stable MLE-12 cells ([Fig. 4d,e](#F4){ref-type="fig"}) under non-stimulated and stimulated (TNF or LPS) conditions. Importantly, LPS-induced increase of C/EBP-δ and IL-6 mRNAs in MLE-12--Miz1(ΔPOZ) cells was significantly prolonged in comparison with that in MLE12--Miz1(WT) cells ([Fig. 4f,g](#F4){ref-type="fig"}). Thus, nuclear Miz1 plays a critical role in transcriptional termination of LPS target genes in the late phase of the inflammation.

Miz1 suppresses inflammation by repressing *Cebpd* {#S9}
--------------------------------------------------

We determine whether the augmented production of pro-inflammatory cytokines caused by loss of the Miz1 POZ domain is mediated by C/EBP-δ. C/EBP-δ was specifically knocked down by its siRNA (siC/EBP-δ) in MLE-12--Miz1(ΔPOZ) cells under non-stimulated or stimulated (TNF or LPS) conditions ([Fig. 5a--d](#F5){ref-type="fig"}). When cells were treated with siCtrl, TNF-induced production of pro-inflammatory cytokines and chemokines was significantly enhanced in MLE-12--Miz1(ΔPOZ) cells compared with MLE12--Miz1(WT) cells ([Fig. 5b](#F5){ref-type="fig"}). Silencing of C/EBP-δ almost completely abolished the enhanced production of pro-inflammatory cytokines and chemokines in MLE-12--Miz1(ΔPOZ) cells ([Fig. 5b](#F5){ref-type="fig"}). Similar results were obtained when cells were treated with LPS ([Fig. 5d](#F5){ref-type="fig"}). Thus, suppression of the inflammatory response by Miz1 is dependent on its repression of *Cebpd*.

Miz1 directly represses the promoter activity of*Cebpd* {#S10}
-------------------------------------------------------

To determine the mechanism by which Miz1 represses *Cebpd* transcription, we analyzed the *Cebpd* promoter. Miz1 usually binds to the transcriptional initiator element \[YYAN-T/A-YYY, Y: C or T (pyrimidines), N: any bases, T/A: T or A\] in the promoter of its target genes^[@R39]^. Sequence analysis revealed that there is a putative Miz1 binding site located in the proximal region \[CCAGTCCC, −98 \~ −92, relative to transcriptional start site (TSS)\] of the *Cebpd* promoter ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). Indeed, Miz1 was associated with the proximal but not the control distal region of the *Cebpd* promoter ([Supplementary Fig. 4a--c](#SD1){ref-type="supplementary-material"}), consistent with the previous report^[@R40]^. Under non-stimulated conditions, a small amount of Miz1 was already recruited to the *Cebpd* promoter in MLE-12 cells ([Fig. 6a](#F6){ref-type="fig"}). The recruitment was further enhanced 3 h after TNF stimulation ([Fig. 6a](#F6){ref-type="fig"}). By contrast, Miz1 was not recruited to the promoter of *Cebpb* ([Fig. 6a](#F6){ref-type="fig"}). Similar results were obtained when cells were treated with LPS ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}). The recruitment of Miz1 was dependent on the POZ domain, as the recruitment of Miz1(ΔPOZ) mutant to the *Cebpd* promoter was almost diminished ([Fig. 6b](#F6){ref-type="fig"}).

To determine whether the recruitment of Miz1 to the *Cebpd* promoter is required for repressing Cebpd transcription, HEK293 cells were co-transfected with a *Cebpd* luciferase reporter gene along with or without expression vectors encoding wild-type Miz1 or Miz1(ΔPOZ) mutant. Wild-type Miz1, but not Miz1(ΔPOZ) mutant, significantly repressed the *Cebpd* promoter activity under resting and TNF-stimulated conditions ([Fig. 6c](#F6){ref-type="fig"}). Similar results were obtained using MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) stable cells ([Fig. 6d](#F6){ref-type="fig"}). These data demonstrate that Miz1 directly represses *Cebpd* transcription under non-stimulated and stimulation conditions.

Miz1 via HDAC1 represses the *Cebpd* promoter {#S11}
---------------------------------------------

We determined whether Miz1 via HDACs^[@R41]^ represses *Cebpd* expression. First, we examined whether HDAC1 regulates *Cebpd* promoter activity. Silencing of HDAC1 ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}) significantly enhanced C/EBP-δ-luciferase reporter gene activity and *Cebpd* transcription ([Fig. 6e](#F6){ref-type="fig"}) in TNF-treated MLE-12 cells. Consistently, treatment with trichostatin (TSA), a specific inhibitor of histone deacetylases, increased histione acetylation on the *Cebpd* promoter in TNF-treated MLE-12 cells ([Fig. 6f](#F6){ref-type="fig"}). Thus, HDAC1 is involved in regulation of *Cebpd* promoter activity.

To determine whether Miz1 via HDAC1 regulates the *Cebpd* promoter activity, we used ChIP assays. The association between HDAC1 and the *Cebpd* promoter was readily detectable in resting MLE12--Miz1(WT) cells ([Fig. 6g](#F6){ref-type="fig"}). The association was only modestly reduced in MLE-12--Miz1(ΔPOZ) cells ([Fig. 6g](#F6){ref-type="fig"}), suggesting that under resting conditions, the association of HDAC1 with the *Cebpd* promoter does not solely depend on nuclear Miz1. Indeed, p50, which is a member of the NF-κB family but itself has no transcriptional activity, also bound at the *Cebpd* promoter and silencing of p50 reduced HDAC1 binding at the *Cebpd* promoter under non-stimulated conditions ([Supplementary Fig. 4f,g](#SD1){ref-type="supplementary-material"}). Thus, both Miz1 and p50 are involved in HDAC1 binding at the *Cebpd* promoter under non-stimulated conditions.

Next, we determined whether Miz1 recruits HDAC1 to the *Cebpd* promoter upon TNF stimulation. Two h after TNF stimulation, during which time Miz1 constitutively, though weakly, bound to the *Cebpd* promoter ([Fig. 6a](#F6){ref-type="fig"}), HDAC1 was released from the *Cebpd* promoter in both MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells ([Fig. 6g](#F6){ref-type="fig"}). This finding suggests that the temporary release of HDAC1, which may allow *Cebpd* to be transiently transcribed ([Fig. 4f](#F4){ref-type="fig"}), is not regulated by Miz1. Interestingly, the binding of p50 on the *Cebpd* promoter was reduced 1--2 h after TNF stimulation, while RelA was recruited to the promoter ([Supplementary Fig. 4f,h](#SD1){ref-type="supplementary-material"}). The replacement of p50 by RelA may relieve the repression by p50, allowing C/EBP-δ to be transiently transcribed upon TNF stimulation, consistent with previous reports^[@R42]^. The reason for a small amount of Miz1 to remain on the promoter of C/EBP-δ during this time is probably to prevent excessive expression of C/EBP-δ upon TNF stimulation.

In the late phase (3--4 h) of TNF stimulation, when Miz1 was further recruited to the *Cebpd* promoter ([Fig. 6a](#F6){ref-type="fig"}), HDAC1 was recruited again to the *Cebpd* promoter in MLE12--Miz1(WT) but not MLE-12--Miz1(ΔPOZ) cells ([Fig. 6g](#F6){ref-type="fig"}). This result suggests that Miz1 is required for the re-recruitment of HDAC1 to the *Cebpd* promoter. Although histone acetylation of the *Cebpd* promoter was increased in both MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells 2 h after TNF stimulation ([Fig. 6h](#F6){ref-type="fig"}), it was significantly reduced in MLE12--Miz1(WT) but not in MLE-12--Miz1(ΔPOZ) cells at the late phase of TNF stimulation ([Fig. 6h](#F6){ref-type="fig"}). Consistently, the recruitment of RNA polymerase II to the *Cebpd* promoter was decreased in MLE12--Miz1(WT) but not in MLE-12--Miz1(ΔPOZ) cells 3 h after TNF stimulation ([Supplementary Fig. 4i](#SD1){ref-type="supplementary-material"}). Furthermore, silencing of HDAC1 enhanced *Cebpd* transcription in MLE12--Miz1(WT) but only had minimal effects in MLE-12--Miz1(ΔPOZ) cells ([Fig. 6i](#F6){ref-type="fig"}). These data suggest that the Miz1 POZ domain is required for TNF-induced re-recruitment of HDAC1 to the *Cebpd* promoter to silence *Cebpd* transcription in the late phase of the inflammation.

Miz1 controls NF-κB and ATF-3 binding to *Cebpd* promoter {#S12}
---------------------------------------------------------

We wondered whether loss of the Miz1 POZ domain affects the binding of NF-κB and ATF-3 to the *Cebpd* promoter. Semi-quantitative RT-PCR and immunoblotting analysis revealed that expression of NF-κB subunits (RelA, RelB, c-Rel, p50, and p52) was similar between MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells, while expression of ATF-3 was reduced in MLE-12--Miz1(ΔPOZ) cells ([Fig. 7a,b](#F7){ref-type="fig"}). ChIP analysis showed that the binding of Miz1 on the *Cebpd* promoter was persistent in MLE12--Miz1(WT) but was reduced in MLE-12--Miz1(ΔPOZ) cells ([Fig. 7c](#F7){ref-type="fig"}), consistent with our data ([Fig. 6a](#F6){ref-type="fig"}) and previous reports that the POZ domain is essential for Miz1 DNA binding^[@R11],[@R12],[@R14]^. The binding of RelA on the *Cebpd* promoter was transient in MLE12--Miz1(WT) cells but sustained in MLE-12--Miz1(ΔPOZ) cells ([Fig. 7d](#F7){ref-type="fig"}). This result suggests that Miz1 may negatively regulate the binding of RelA, probably through HDAC1-mediated histone deacetylation ([Fig. 6](#F6){ref-type="fig"}), as acetylation is a pre-requisite for the recruitment of NF-κB to its target promoters^[@R43]^. By contrast, TNF-induced ATF-3 binding on the *Cebpd* promoter was delayed and reduced in MLE-12--Miz1(ΔPOZ) cells ([Fig. 7e](#F7){ref-type="fig"}), suggesting that Miz1 may positively regulate the binding of ATF-3 on the *Cebpd* promoter, probably through controlling ATF-3 transcription ([Fig. 7a,b](#F7){ref-type="fig"}). These data demonstrate that the binding of RelA, Miz1 and ATF-3 to the *Cebpd* promoter is temporally coordinated and that Miz1 regulates the binding of RelA and ATF-3 to the *Cebpd* promoter.

Phosphorylation of Miz1 is required for repressing *Cebpd* {#S13}
----------------------------------------------------------

To determine how Miz1-mediated transcriptional repression of *Cebpd* is regulated by TNF, we analyzed the post-translational modifications of Miz1 upon TNF stimulation. MS/MS spectrometry analysis revealed that Miz1 was phosphorylated at a unique site, Ser178, which is located between the POZ domain and the first zinc finger, in lung epithelial cells 1 h after TNF stimulation ([Fig. 8a](#F8){ref-type="fig"}). While ectopic expression of wild-type Miz1 in MLE-12--Miz1(KD) cells suppressed TNF-induced *Cebpd*-luciferase reporter gene activity, expression of the non-phosphorylatable Miz1(S178A) mutant failed to do so ([Fig. 8b](#F8){ref-type="fig"}).

To further determine the function of Miz1 Ser178-phosphorylation, we used stable MLE-12 cells, in which endogenous Miz1 was knocked down by specific shRNA ([Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}) and simultaneously wild-type or the Miz1(S178A) mutant containing silent mutations to make it resistant to Miz1 shRNA was similarly expressed \[MLE12--Miz1(WT) and MLE-12--Miz1(S178A) cells\] ([Fig. 8c](#F8){ref-type="fig"}). Real-time RT-PCR and Cytometric Bead Array (CBA) analysis revealed that TNF-induced *Cebpd* transcription and IL-6 production were significantly augmented in MLE-12--Miz1(S178A) cells ([Fig. 8c](#F8){ref-type="fig"}). Mutation of Ser178 to alanine had no detectable effects on the binding of Miz1 on the *Cebpd* promoter under non-stimulation conditions but almost completely abolished the recruitment of Miz1 to the *Cebpd* promoter upon TNF stimulation ([Fig. 8d](#F8){ref-type="fig"}). Consistently, the re-recruitment of HDAC1 to the *Cebpd* promoter was significantly reduced in MLE-12--Miz1(S178A) cells 3--4 h after TNF stimulation ([Fig. 8e](#F8){ref-type="fig"}). Note that TNF-induced activation of MAP kinases (JNK, p38, or ERK), or IKK, was comparable between MLE12--Miz1(WT) and MLE-12--Miz1(S178A) cells ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}), suggesting that Miz1 Ser178-phosphorylation is not involved in regulation of its cytoplasmic activity. Taken together, TNF-induced Ser178-phosphorylation is a pre-requisite step for TNF-induced recruitment of Miz1 to the *Cebpd* promoter to repress its transcription via further recruiting HDAC1, thereby inhibiting the production of cytokines like IL-6.

DISCUSSION {#S14}
==========

Inflammation is tightly controlled by a complex regulatory network^[@R11],[@R16]^. While the mechanisms underlying the initiation and amplification of the inflammatory response are extensively studied, how the inflammatory response is temporally resolved is not completely understood. In this report, we demonstrate that the transcription factor Miz1 is a key regulator in constraining LPS-induced inflammatory response through histone deacetylation-mediated transcriptional repression of *Cebpd* in a pathophysiological setting.

C/EBP-δ is responsible for LPS-induced persistent inflammation and its expression is positively regulated by NF-κB but negatively regulated by ATF-3^[@R9]^. Genetic disruption of the Miz1 POZ domain significantly enhanced the transcription of *Cebpd* and other LPS-target genes such as *Il6*. Thus, nuclear Miz1 is another negative regulator of C/EBP-δ. Miz1 also regulates basal C/EBP-δ expression. In Miz1 POZ domain-deficient cells or mice, C/EBP-δ expression was already up-regulated under non-stimulated conditions, even though there was no detectable increase in expression of pro-inflammatory cytokines or inflammation. This suggests that up-regulation of C/EBP-δ alone is not sufficient to initiate inflammation. However, the up-regulated C/EBP-δ may promote the initiation of inflammation when cells are stimulated by inflammatory signals, likely through its cooperation with NF-κB^[@R5]^. Indeed, loss of the Miz1 POZ domain accelerated the induction of pro-inflammatory cytokines. Thus, Miz1 regulates LPS-induced inflammation through repression of both basal and stimulated C/EBP-δ expression.

Unlike ATF-3, which only affects the strength but not the duration of LPS-induced transcription of *Cebpd* and other LPS-target genes^[@R9]^, loss of the Miz1 POZ domain resulted in sustained augmentation of *Cebpd* transcription, leading to persistent inflammatory response in the LPS model. Consistently, Miz1 also suppressed the inflammatory response in mice with *P. aeruginosa* pneumonia. Thus, nuclear Miz1 plays a critical role in termination of LPS-induced inflammation and functions as a guardian that constrains TLR4-mediated hyperinflammation, thereby preventing acute lung injury and reducing mortality in LPS-treated mice.

Our study reveals that Miz1 is a novel component in the NF-κB-ATF-3-C/EBP-δ transcriptional regulatory circuit. Nuclear Miz1 not only directly repressed *Cebpd* transcription, it also affected the recruitment of NF-κB/RelA, the initiator of the transcriptional regulatory circuit^[@R11]^, to the *Cebpd* promoter. Loss of the Miz1 POZ domain diminished the re-recruitment of HDAC1 and the histone deacetylation on the *Cebpd* promoter. This may be accountable for sustained binding of NF-κB/RelA on the *Cebpd* promoter in Miz1(ΔPOZ) cells, as histone acetylation usually precedes RelA binding to the promoters of its target genes^[@R43]^. The persistent binding of RelA on the *Cebpd* promoter in the absence of the Miz1 POZ domain upon TNF stimulation occurred long after IκBα resynthesis, suggesting that newly synthesized IκBα is not sufficient to promote NF-κB/RelA removal from its target promoters, consistent with previous reports^[@R43]^. On the other hand, Miz1 controlled expression of ATF-3 and consequently the amount of ATF-3 proteins binding to the *Cebpd* promoter. Thus, Miz1 terminates expression of the inflammatory genes in the late phase of the TLR4- and TNF-R1-mediated inflammatory responses through, at least, two mechanisms. First, Miz1 directly binds to the *Cebpd* promoter and recruits HDAC1, thereby interfering with NF-κB/RelA binding and repressing *Cebpd* transcription. Second, Miz1 upregulates ATF-3 expression, thereby indirectly repressing *Cebpd* transcription^[@R11]^. Future studies are needed to determine how Miz1 regulates ATF-3 expression.

Phosphorylation of Miz1 is involved in suppression of TNF-induced inflammation. Upon TNF stimulation, Miz1 was phosphorylated at a unique site Ser178 and the phosphorylation was required for Miz1 to bind to the *Cebpd* promoter and recruit HDAC1 at the late phase of the inflammation to repress *Cebpd* transcription and IL-6 production. Thus, Ser178-phosphorylation may control the transcriptional repression activity of Miz1 in TNF-induced inflammation. One of the possible mechanisms is that the phosphorylation may enable Miz1 to recruit additional factor(s) to stabilize its binding on the *Cebpd* promoter. Further studies are needed to test this hypothesis and to determine which protein kinase(s) phosphorylates Miz1 at Ser178 in response to TNF stimulation.

Miz1 serves as a dual checkpoint in regulation of LPS-induced inflammation. Previously, we reported that cytoplasmic Miz1 suppresses LPS- or TNF-induced production of pro-inflammatory cytokines through inhibition of TRAF2-mediated JNK activation, independently of its transcriptional activity^[@R16]--[@R18]^. The inhibition is rapidly released after the stimulation (\<15 min) when TRAF2-associated Miz1 is ubiqutinated by the E3 ligase Mule and subsequently degraded by the 26S proteasome, suggesting that cytoplasmic Miz1 is involved in restraining the onset rate of LPS or TNF-induced inflammatory responses^[@R27],[@R29]^. Our current data show that nuclear Miz1 suppresses LPS-induced persistent inflammation by transcriptional repression of *Cebpd*, the amplifier that controls expression of a large number of LPS-target genes, thereby constraining the inflammatory response. Thus, Miz1 may function as a dual checkpoint that temporally and spatially modulates LPS-induced inflammatory response, thereby preventing the host from tissue damage and organ failure.

METHODS {#S15}
=======

Mice {#S16}
----

*Miz1*(POZ)^fl/fl^ mice on the C57BL/6 background have been described previously^[@R22]^. The animal care and experiments were performed in compliance with the institutional and US National Institutes of Health guidelines and were approved by the Northwestern University Animal Care and Use Committee. For the mortality studies, when mice developed a moribund condition (hunched posture, lack of curiosity, little or no response to stimuli and not moving when touched), which is a clinically irreversible condition leading to inevitable death according to the guidelines for selecting humane endpoints in rodent studies at Northwestern University, they were euthanized.

Reagents {#S17}
--------

TNF was from R&D Systems. LPS (L2630), TSA, poly(I:C) and the β-actin antibody (AC-15) were from Sigma-Aldrich. The antibodies against Miz1 (H-190), C/EBP-α (D-5), C/EBP-β (H-7), C/EBP-δ (C-6), RelA (C-20), RelB (C-19), c-Rel (N-466), p50 (E-10), p52 (K-27), RNA polymerase II (N-20) and ATF-3 (C-19) were from Santa Cruz Biotechnology. The antibodies against p-JNK, JNK, p-c-Jun, c-Jun, p-ERK1/2, ERK1/2, p-p38, p38, p-IKK, IKKβ and IκBα have been described previously^[@R16]--[@R18]^. The C/EBP-δ siRNA oligonucleotides (5′-AGCAGAAGCTGGTGGAGTT-3′), HDAC1 siRNA oligos (5′-GCAGATGCAGAGATTCAAT-3′), Miz1 siRNA oligonucleotides (5′-TGCTGAACCTGCATAGAA-3′) and p50 siRNA oligonucleotides (5′-AGTCCAGGATTATAGCCCC-3′) were from Thermo Scientific (Dharmacon products). The *Cebpd* luciferase reporter gene construct was a generous gift from J. Dewille (Ohio State University College of Veterinary Medicine).

Virus infection {#S18}
---------------

Ad-null and Ad-Cre were purchased from ViraQuest. Ad-SPC-Cre and null or Cre lentivirus were from Gene Transfer Vector Core of University of Iowa. Mice were infected intratracheally with 1×10^9^ pfu (plaque forming units) adenovirus/mouse. ATII cells were infected with adenovirus and bone marrow cells were infected with lentivirus at 50 moi (multiplicity of infection) on the day of isolation.

LPS-induced lung inflammation and injury model {#S19}
----------------------------------------------

Ad-treated male WT or *Miz1*(POZ)^fl/fl^ mice (6--8 weeks old) were intratracheally instilled with LPS (6 mg/kg). After 2, 7 or 10 d as indicated, the BAL fluid was collected for cell counts, cell differentials, and protein quantification. The lungs were fixed, embedded in paraffin, and analyzed by H&E staining. In some experiments, the BAL fluid was collected 8 h after LPS treatment for cytokine/chemokine analysis, and lung tissues were harvested for immunoblotting. For the mortality studies, mice were intratracheally treated with a low dose (6 mg/kg) or high dose (12 mg/kg) of LPS and monitored twice daily for up to 7 d.

Mouse model of acute pneumonia {#S20}
------------------------------

Ad-treated Male *Miz1*(POZ)^fl/fl^ mice (6--8 weeks old) were intranasally inoculated with *P. aeruginosa* \[strain PA103, 2×10^5^ CFU (colony forming units)/mouse\], as previously described^[@R44]^. Sixteen h post-infection, cytokine and chemokine production in BAL were determined. To examine bacterial load, mice were euthanized and lungs, livers, and spleens were aseptically removed, homogenized in PBS and plated on LB agar. CFU in these organs were counted. For survival experiments, mice were monitored every 8 h for up to 7 d.

Analysis of cytokines and chemokines {#S21}
------------------------------------

The cytokine/chemokine concentrations in the BAL fluid or cell culture supernatants were quantified using the cytometric bead array kit for mouse pro-inflammatory cytokines and chemokines (CBA; BD Biosciences).

Isolation of mouse ATII and lung hematopoietic-derived cells {#S22}
------------------------------------------------------------

ATII cells were isolated as described^[@R21],[@R45]^. Briefly, perfused and lavaged lungs were digested with dispase (1 ml, BD Bioscience) and purified by negative immunoselection using a mixture of antibodies, including anti-CD16/32 (2.4G2, BD Biosciences), anti-TER-119 (TER-119, BD Biosciences), anti-CD45 (30-F11, BD Biosciences), and anti-CD90 (OX-7, BD Biosciences), followed by differential adherence to dishes. Cells were cultured in DMEM containing 10% FBS with 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. The cell viability was assessed by Trypan Blue (\>95%). For isolating lung hematopoietic-derived cells, perfused and lavaged lungs were digested with collagenase and purified using percoll density gradients (40%/80%).

Generation of stable cell lines, siRNA transfection, and TSA treatment {#S23}
----------------------------------------------------------------------

MLE-12 cells were transduced with lentiviral particles encoding shRNA against Miz1 (shMiz1; SHCLNG-NM_009541, Sigma) or a scrambled shRNA control (shCtrl; SHC002, Sigma) and selected in 5 µg/ml puromycin, according to the manufacturer's instructions. Cells were then transfected with pcDNA3.1 vector encoding WT Miz1, the Miz1(ΔPOZ) mutant, or the Miz1(S178A) mutant (all three constructs contain silent mutations that make them resistant to shMiz1) and selected by G418 (300 µg/ml). For the siRNA transfections, cells were transfected with the siRNAs (100 nM). Twenty-four h later, cells were serum-starved for 24 h and treated with or without TNF (5 ng/ml) or LPS (500 ng/ml) for 6 h or various times as indicated. The supernatants were collected for cytokine analysis, and the cell lysates were analyzed by immunoblotting or qRT-PCR. For TSA treatment, cells were pre-treated with TSA (100 ng/ml) for 2 h before stimulation with TNF.

Genomic DNA PCR, RT-PCR, ChIP assays and *Cebpd* luciferase reporter gene assays {#S24}
--------------------------------------------------------------------------------

Genomic DNA or RNA from the lungs of WT or Ad-treated *Miz1*(POZ)^fl/fl^ mice or cells was isolated using DNAzol (Invitrogen) or RNAzol (Invitrogen), respectively. For genomic DNA PCR, primers flanking the first *lox*P site were used (primer 1, 5′-GTATTCTGCTGTGGGGCTATC-3′; primer 2, 5′-GGCTGTGCTGGGGGAAATC-3′). The following primers were used for RT-PCR: primer 3, 5′-CGTTGACTTCAAGGCTCACA-3′; primer 4, 5′-GTCCACGTTCTCAGGGCTAA-3′; primer 5, 5′-GGCAGAGAACTCAAGGAGGA-3′; primer 6, 5′-GTCCGTCTTCTCCTTTGCTG-3′; mouse C/EBP-δ, sense 5′-CGCAGACAGTGGTGAGCTT-3′/anti-sense 5′-CTTCTGCTGCATCTCCTGGT-3′; mouse IL-6, sense 5′-AGTTGCCTTCTTGGGACTGA-3′/anti-sense 5′-TCCACGATTTCCCAGAGAAC-3′; mouse RelA, sense 5′-GGCCTCATCCACATGAACTT-3′/anti-sense 5′-CACTGTCACCTGGAAGCAGA-3′; mouse RelB, sense 5′-TGATCCACATGGAATCGAGA-3′/anti-sense 5′-CAGGAAGGGATATGGAAGCA-3′; mouse c-Rel, sense 5′-TGCTGGACATTGAAGACTGC-3′/anti-sense 5′-CCCCTGACACTTCCACAGTT-3′; mouse p50, sense 5′-CTGACCTGAGCCTTCTGGAC-3′/anti-sense 5′-GCAGGCTATTGCTCATCACA-3′; mouse p52, sense 5′-TGACTGTGGAGCTGAAGTGG-3′/anti-sense 5′-GGTGTGTTTCCAGCAAAGGT-3′; mouse ATF-3, sense 5′-CTAGAATCCCAGCAGCCAAG-3′/anti-sense 5′-GGCCAGCTAGGTCATCTGAG-3′. For quantitative real-time RT-PCR, expression of C/EBP-δ and IL-6 mRNAs was normalized to that of GADPH. The ChIP assays were performed as previously described^[@R46]^. For the immunoprecipitation, 2 µg of antibody was used. Anti-Miz1 (H-190, Santa Cruz Biotechnology), anti-HDAC1 (2E10, Upstate), anti-acetyl lysine (K9, K14) histone H3 (06--599, Upstate), anti-histone H3 (FL-136, Santa Cruz), anti-RNA polymerase II (N-20, Santa Cruz), anti-RelA (C-20, Santa Cruz), anti-ATF-3 (C-19, Santa Cruz), anti-p50 (E-10, Santa Cruz) or control IgG (2 µg each) was used for immunoprecipitation from an equal amount of chromatin (50--100 µg). DNA from immunoprecipitated protein was quantified by real-time PCR. Data are presented from three independent experiments, normalized to input DNA. The sequences of the promoter-specific primers are: C/EBP-δ (proximal), sense 5′-GCGTGTCGGGGCCAAATCCA-3′/antisense 5′-TTTCTAGCCCCAGCTGACGCGC-3′; C/EBP-δ (distal), sense 5′-TGCTTCTATGGCATCCAG-3′/antisense 5′-GAGGGGCTGTGGAATATT-3′; C/EBP-β, sense 5′-GCACCTGGAGAGTTCTGCTT-3′/antisense 5′-ATCGTTCCTCCAGCTACACG-3′. For the *Cebpd* luciferase reporter gene assays, the *Cebpd* luciferase reporter gene construct (0.5 µg) and a Renilla luciferase reporter construct (1 ng) were transfected into HEK293 cells along with or without WT Miz1 or the Miz1(ΔPOZ) mutant constructs (0.5 µg), or into MLE12--Miz1(WT) or MLE-12--Miz1(ΔPOZ) cells. Twenty-four h later, cells were serum-starved for 24 h and treated with or without TNF (5 ng/ml) for 12 h. Cells were harvested and assayed for firefly and renilla luciferase activities. The C/EBP-δ luciferase activity was normalized to the renilla luciferase activity.

TNF and LPS stimulation *in vitro* {#S25}
----------------------------------

Cells were serum-starved for 24 h and treated with TNF (5 ng/ml) or LPS (500 ng/ml) for various times as indicated. The supernatants were collected for cytokine analysis, and/or cells were lysed for immunoblotting or RT-PCR.

Lung permeability assay {#S26}
-----------------------

Lung permeability was measured by Evan's blue dye (EBD) leakage from blood to airways^[@R47]^. EBD (20 mg/kg; Sigma) was intravenously injected into Ad-treated *Miz1*(POZ)^fl/fl^ mice. One h later, lungs were perfused, removed, and photographed. EBD was extracted in formamide (Sigma) at 37 °C for 24 h, quantitated spectrophotometrically at 620 and 740 nm and calculated as EBD = OD~620~ − (1.426 × OD~740~ + 0.030). The permeability of the alveolar-capillary membrane to FITC-dextran (4 kDa) was also measured^[@R48]^. Briefly, 125 µl of 0.05 g/ml FITC-dextran (Sigma) was delivered into the retro-orbital plexus of Ad-treated *Miz1*(POZ)^fl/fl^ mice. Thirty min later, BAL and blood from the right ventricle were collected. The fluorescence was measured (excitation, 488 nm; emission, 530 nm). Lung permeability was calculated by the ratio of the fluorescence of the plasma to the BAL. For lung wet/dry ratio, after weighing, perfused lungs were heated at 65 °C and weighed every 24 h until a stable dry weight was obtained (usually 72 h).

Bone Marrow Chimeras {#S27}
--------------------

Bone marrow cells isolated from *Miz1*(POZ)^f/f^ mice (C57BL/6; CD45.2^+^) were transduced with null or Cre lentivirus and then intravenously transferred into lethally irradiated wild-type recipient (B6.SJL-*Ptprc^a^*/BoyAiTac; CD45.1^+^) mice. Six weeks later, peripheral blood samples were collected, and mononuclear cells were stained with anti-CD45.1 (A20, eBioscience) and anti-CD45.2 (104, eBioscience). Expression of CD45.1 and CD45.2 was analyzed by flow cytometry to examine bone marrow reconstitution. Lung ATII and hematopoietic-derived cells were isolated and expression of the Miz1 POZ domain was analyzed by real-time RT-PCR.

Statistical analysis {#S28}
--------------------

Data were analyzed by Student's *t*-test, and the results are presented as the mean ± the standard error of the mean (s.e.m.).
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![Mice with lung-specific disruption of the Miz1 POZ domain are highly susceptible to LPS-induced inflammation and acute lung injury\
(**a**) WT or *Miz1*(POZ)^fl/fl^ mice were intratracheally transduced with Ad-null or Ad-Cre for 30 d. The lung tissues were isolated and analyzed by Miz1 allele-specific genomic PCR. ▸ indicates *lox*P sites; arrows plus numbers (1, 2) indicate positions of primers. (**b**) Immunoblotting analysis of Miz1 in ATII cells isolated from Ad-null or Ad-Cre-treated *Miz1*(POZ)^fl/fl^ mice. (**c,d**) H&E staining of lung sections (**c**) and BAL fluid cell differentials (**d**) from WT or *Miz1*(POZ)^fl/fl^ mice that were intratracheally transduced with Ad-null or Ad-Cre for 30 d and then treated with intratracheal PBS or LPS for 2 d. Five mice per group were examined in three independent experiments (**a--d**). (**e**) *Miz1*(POZ)^fl/fl^ mice (*n* = 5 mice per time point) were intratracheally transduced with Ad-null or Ad-Cre for 30 d and then intratracheally treated with PBS or LPS for 2, 7 and 10 d. Lung histology was analyzed. (**f**) Survival of Ad-null or Ad-Cre-treated *Miz1*(POZ)^fl/fl^ mice (*n* = 10 mice per group) after challenge with LPS at a high dose (12 mg/kg). (**g**) *Miz1*(POZ)^fl/fl^ mice (*n* = 5 mice per group) were intratracheally transduced with Ad-null, Ad-Cre, or Ad-SPC-Cre for 30 d and then intratracheally treated with PBS or LPS for 2 d. Lung histology was analyzed. Data are representative of three independent experiments (**e--g**).](nihms441308f1){#F1}

![Loss of the Miz1 POZ domain augments the production of pro-inflammatory cytokines and chemokines *in vivo* and *in vitro*\
(**a--d**) WT or *Miz1*(POZ)^fl/fl^ mice (*n* = 5 mice per group) were intratracheally transduced with Ad-null or Ad-Cre for 30 d and then treated with intratracheal PBS or LPS for 8 h. The production of TNF (**a**), IL-6 (**b**), IL-1β (**c**), and MCP-1 (**d**) in the BAL fluid was analyzed. (**e,f**) The production of pro-inflammatory cytokines and chemokines in ATII cells isolated from *Miz1*(POZ)^fl/fl^ mice and infected with Ad-null \[ATII-Miz1(WT)\] or Ad-Cre \[ATII-Miz1(ΔPOZ)\], followed by the treatment with or without TNF or LPS for 8 h (**e**), or in MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells treated with or without TNF or LPS for 8 h (**f**). Data are representative of at least three independent experiments (means ± s.e.m.) (**a--f**). \*, *P* \< 0.05 by Student's *t*-test.](nihms441308f2){#F2}

![Loss of the Miz1 POZ domain increases inflammatory cytokine and chemokine production, promotes bacterial clearance and improves survival in mice with *P. aeruginosa* pneumonia\
*Miz1*(POZ)^fl/fl^ mice (*n* = 5 mice per group except for **c**, in which *n* = 10 mice per group) were intratracheally transduced with Ad-null or Ad-Cre for 30 d and then intranasally inoculated with *P. aeruginosa* (strain PA103, 2×10^5^ CFU/mouse). Sixteen h after the inoculation, cytokines and chemokines in the BAL fluid (**a**) as well as bacterial loads in the lung, liver and spleen (**b**) were determined. Mortality of the mice was monitored every 6 h for up to 4 d (**c**). \*, *P* \< 0.05 by Student's *t*-test. Data are representative of two independent experiments.](nihms441308f3){#F3}

![Genetic disruption of the Miz1 POZ domain upregulates *Cebpd* transcription *in vivo* and *in vitro*\
(**a**) *Miz1*(POZ)^fl/fl^ mice were intratracheally transduced with Ad-null or Ad-Cre for 30 d and then intratracheally treated with PBS or LPS for 8 h. Protein and mRNA abundance of C/EBP isoforms in the lungs were determined. (**b,c**) Analysis of C/EBP-δ protein and mRNA expression in ATII cells that were isolated from *Miz1*(POZ)^fl/fl^ mice, infected with Ad-null or Ad-Cre, and then treated with TNF (**b**) or LPS (**c**) for 4 h. (**d,e**) Protein or mRNA levels of C/EBPs in MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells treated with TNF (**d**) or LPS (**e**) for 4 h. Results are representative of at least three independent experiments (**a--e**). (**f,g**) Analysis of mRNA levels of C/EBP-δ (**f**) and IL-6 (**g**) in MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells treated with LPS for different times as indicated. Data are representative of three independent experiments (means ± s.e.m.).](nihms441308f4){#F4}

![Silencing of C/EBPδ abrogates the effect of loss of the Miz1 POZ domain on the production of pro-inflammatory cytokines and chemokines\
Analysis of TNF-(**a,b**) or LPS-induced (**c,d**) production of pro-inflammatory cytokines and chemokines in MLE-12--Miz1(ΔPOZ) cells transfected with control siRNA or C/EBP-δ siRNA. MLE12--Miz1(WT) cells were used as control. Data are representative of at least three independent experiments (means ± s.e.m.). \*, P \< 0.05 by Student's *t*-test.](nihms441308f5){#F5}

![Miz1 recruits HDAC1 to the promoter of *Cebpd* to repress its transcription\
(**a**) ChIP analysis of Miz1 recruitment to the *Cebpd* or *Cebpb* promoter in MLE-12 cells treated with or without TNF. ND, not detected. (**b**) ChIP analysis of Miz1 recruitment to the *Cebpd* promoter in MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells treated with or without TNF. (**c,d**) *Cebpd* luciferase reporter gene assays in HEK293 cells expressing WT Miz1 or the Miz1(ΔPOZ) mutant (**c**) or in MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells (**d**). Cells were treated with or without TNF (**c,d**). (**e**) *Cebpd* luciferase reporter gene assays and C/EBP-δ qRT-PCR (normalized to GAPDH) in MLE-12 cells transfected with the scramble control siRNA (siCtrl) or HDAC1 siRNA and then treated with or without TNF. (**f**) ChIP assays using anti-acetyl lysine (K9, K14) histone H3 (Ac-H3) and histone H3 (H3) for immunoprecipitation in TNF-treated MLE-12 cells in the absence or presence of TSA. Ac-H3 ChIP data were normalized to H3 ChIP data. (**g,h**) HDAC1 ChIP (**g**) and Ac-H3 ChIP (normalized to H3 ChIP) (**h**) assays in MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells treated with or without TNF. (**i**) qRT-PCR of C/EBP-δ (normalized to GAPDH) in MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells transfected with siCtrl or HDAC1 siRNA and then treated with or without TNF. Data are representative of three independent experiments (**a--i**) and presented as the means ± s.e.m. \*, *P* \< 0.05 by Student's *t*-test.](nihms441308f6){#F6}

![TNF-induced recruitment of NF-κB/RelA and ATF-3 to the *Cebpd* promoter is altered by loss of the Miz1 POZ domain\
(**a,b**) Analysis of mRNA (**a**) and protein (**b**) abundance of NF-κB components (RelA, RelB, c-Rel, p50 and p52) and ATF-3 in non-stimulated MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells. (**c--e**) ChIP analysis of the recruitment of Miz1 (**c**), RelA (**d**), and ATF-3 (**e**) in MLE12--Miz1(WT) and MLE-12--Miz1(ΔPOZ) cells treated with or without TNF. Data are representative of three independent experiments (**a--e**) and presented as the means ± s.e.m. (**c--e**).](nihms441308f7){#F7}

![Phosphorylation of Miz1 at Ser178 is required for its suppression of *Cebpd* transcription\
(**a**) MLE12--Miz1(WT) cells were treated with or without TNF for 1 h. Xpress-Miz1 was immunoprecipitated with anti-Xpress antibody and resolved by SDS-PAGE, followed by Coomassie Brilliant Blue staining. Xpress-Miz1 band was excised and subjected to MS/MS analysis by the Mass Spectrometry Core Facility at Yale University. (**b**) *Cebpd* luciferase reporter gene assays in MLE-12--Miz1(KD) cells transfected with WT Miz1 or the Miz1(S178A) mutant and then treated with or without TNF. (**c,d,e**) C/EBP-δ transcription and IL-6 production (**c**) as well as ChIP analysis of the recruitment of Miz1 (**d**) and HDAC1 (**e**) to the *Cebpd* promoter were determined in MLE12--Miz1(WT) and MLE-12--Miz1(S178A) cells treated with or without TNF. Data are representative of three independent experiments (**b--e**). \*, *P* \< 0.05 by Student's *t*-test.](nihms441308f8){#F8}
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